{"id":"losartan-and-amlodipine-and-hydrochlorothiazide","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Dizziness"},{"rate":"3-8","effect":"Fatigue"},{"rate":"5-10","effect":"Headache"},{"rate":"2-5","effect":"Hyperuricemia"},{"rate":"3-7","effect":"Hypokalemia"},{"rate":"5-15","effect":"Peripheral edema"},{"rate":"1-3","effect":"Cough"}]},"_chembl":{"chemblId":"CHEMBL1200402","moleculeType":"Small molecule","molecularWeight":"567.06"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Losartan blocks angiotensin II receptors to reduce vasoconstriction and aldosterone secretion. Amlodipine inhibits L-type calcium channels in vascular smooth muscle to promote vasodilation. Hydrochlorothiazide acts as a thiazide diuretic to reduce blood volume and sodium reabsorption. Together, these agents provide synergistic antihypertensive effects.","oneSentence":"This triple-combination antihypertensive reduces blood pressure through three complementary mechanisms: angiotensin II receptor blockade, calcium channel inhibition, and thiazide diuresis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:34:09.768Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension (essential hypertension in patients requiring triple-agent therapy)"}]},"trialDetails":[{"nctId":"NCT03946514","phase":"PHASE4","title":"Efficacy and Safety of a Single-pill Fixed Combination of Sufficient Losartan/Hydrochlorothiazide in Chinese Hypertensive Patients","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2018-09-01","conditions":"Hypertension","enrollment":180},{"nctId":"NCT00157963","phase":"PHASE4","title":"Hydrochlorothiazide (+) Losartan Potassium vs. Amlodipine Comparative Study (0954A-314)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-02-05","conditions":"Essential Hypertension","enrollment":174},{"nctId":"NCT00140959","phase":"PHASE4","title":"Losartan and HCTZ and Amlodipine vs Atenolol and Amlodipine (0954A-309)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-02-01","conditions":"Hypertension","enrollment":120},{"nctId":"NCT06366386","phase":"","title":"Integrating Hypertension Management in DSD for HIV","status":"NOT_YET_RECRUITING","sponsor":"Infectious Diseases Research Collaboration, Uganda","startDate":"2024-06-15","conditions":"Hypertension, HIV","enrollment":1100},{"nctId":"NCT03461003","phase":"PHASE4","title":"N-of-1 Trials In Children With Hypertension","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2018-04-02","conditions":"Pediatric Hypertension","enrollment":49},{"nctId":"NCT02278471","phase":"PHASE2","title":"The SCCS Polypill Pilot Trial","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2015-12","conditions":"Hypertension, Hyperlipidemia","enrollment":303},{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":"Hypertension, COVID","enrollment":22213},{"nctId":"NCT03978884","phase":"PHASE4","title":"Phase 4 Study of the Efficacy of Losartan Based Therapy in Hypertensives With and Without Diabetes","status":"WITHDRAWN","sponsor":"The University of The West Indies","startDate":"2019-06-01","conditions":"Diabetes Mellitus, Hypertension","enrollment":""},{"nctId":"NCT04330300","phase":"PHASE4","title":"Coronavirus (COVID-19) ACEi/ARB Investigation","status":"SUSPENDED","sponsor":"National University of Ireland, Galway, Ireland","startDate":"2020-04-30","conditions":"Hypertension, COVID-19","enrollment":2414},{"nctId":"NCT02744456","phase":"EARLY_PHASE1","title":"N-of-1 Trials for Blood Pressure Medications in Adults","status":"COMPLETED","sponsor":"Columbia University","startDate":"2014-08-01","conditions":"Hypertension, High Blood Pressure","enrollment":10},{"nctId":"NCT01302691","phase":"PHASE3","title":"MK-0954E Study in Participants With Hypertension (MK-0954E-357)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-01-01","conditions":"Hypertension","enrollment":327},{"nctId":"NCT03578042","phase":"PHASE4","title":"Fixed-Free HTN Trial","status":"UNKNOWN","sponsor":"Hotel Dieu de France Hospital","startDate":"2017-04-01","conditions":"Hypertension","enrollment":100},{"nctId":"NCT03147092","phase":"EARLY_PHASE1","title":"Matão Controlling Hypertension (MatCH Study): Rationale and Design","status":"UNKNOWN","sponsor":"Centro Neurológico de Pesquisa e Reabiitação, Brazil","startDate":"2018-02-01","conditions":"Hypertension, Blood Pressure","enrollment":15000},{"nctId":"NCT01964079","phase":"PHASE4","title":"Comparision of Blood Pressure Variability Between Amlodipine and Losartan","status":"COMPLETED","sponsor":"Wonju Severance Christian Hospital","startDate":"2013-04","conditions":"Hypertension","enrollment":144},{"nctId":"NCT02294539","phase":"PHASE4","title":"Comparison of Effects Between Amlodipine and Hydrochlorothiazide in Combination With Losartan on 24-hr Central Blood Pressure in Hypertensive Patients","status":"COMPLETED","sponsor":"Chong-Jin Kim","startDate":"2014-08","conditions":"Hypertension","enrollment":231},{"nctId":"NCT02900729","phase":"PHASE3","title":"Randomized Controlled Trial of Renal Denervation for Resistant Hypertension","status":"UNKNOWN","sponsor":"Shanghai WiseGain Medical Devices Co., Ltd.","startDate":"2016-10","conditions":"Hypertension","enrollment":254},{"nctId":"NCT00492128","phase":"PHASE4","title":"Kanagawa Combination Anti-hypertensive Therapy (K-CAT)","status":"COMPLETED","sponsor":"Yokohama City University Medical Center","startDate":"2007-09","conditions":"Hypertension","enrollment":196},{"nctId":"NCT01176032","phase":"PHASE4","title":"ALiskiren or Losartan Effects on bioMARKers of Myocardial Remodeling","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-06","conditions":"Hypertension, Left Ventricle Hypertrophy","enrollment":74},{"nctId":"NCT01713647","phase":"PHASE1","title":"Bioequivalence Study of Amlodipine / Losartan/ Hydrochlorothiazide of PHARMALINE, Lebanon Under Fastion Conditions","status":"COMPLETED","sponsor":"Pharmaceutical Research Unit, Jordan","startDate":"2012-10","conditions":"Fasting","enrollment":39},{"nctId":"NCT01828359","phase":"PHASE4","title":"The Efficacy and Safety Study of Anti-hypertension Combination Drug in Patients Uncontrolled With Monotherapy.","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2010-08","conditions":"Hypertension","enrollment":199},{"nctId":"NCT01198496","phase":"PHASE4","title":"Recurrent Stroke Prevention Clinical Outcome Study","status":"UNKNOWN","sponsor":"Biomedis International Ltd.","startDate":"2010-10","conditions":"Hypertension, Stroke, Blood Pressure","enrollment":5000},{"nctId":"NCT00446563","phase":"PHASE3","title":"Efficacy and Safety of Valsartan in Combination With Amlodipine Compared to Losartan Plus Hydrochlorothiazide in Patients With Hypertension and Left Ventricular Hypertrophy","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-03","conditions":"Hypertension; Hypertrophy, Left Ventricular","enrollment":90},{"nctId":"NCT01271374","phase":"PHASE4","title":"Changes in Endothelial Function and Biomarkers in African Americans (AA) With Metabolic Syndrome","status":"UNKNOWN","sponsor":"InVasc Therapeutics, Inc.","startDate":"2010-04","conditions":"Hypertension","enrollment":80},{"nctId":"NCT01198249","phase":"PHASE1","title":"Pharmacokinetic Drug Interactions Between Single and Concomitant Administrations of Amlodipine, Losartan, and Hydrochlorothiazide in Subjects With (Pre)Hypertension","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2010-09","conditions":"Essential Hypertension","enrollment":23},{"nctId":"NCT00931710","phase":"PHASE4","title":"Valsartan/Amlodipine As Compared to Losartan Treatment in Stage 2 Systolic Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-07","conditions":"Stage 2 Systolic Hypertension","enrollment":488},{"nctId":"NCT00813722","phase":"PHASE4","title":"Effect of Active Telephone Calls in the Compliance of Hypertensive Patients With Treatment","status":"UNKNOWN","sponsor":"University of Sao Paulo","startDate":"1999-03","conditions":"Blood Pressure","enrollment":400}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Losartan and amlodipine and hydrochlorothiazide","genericName":"Losartan and amlodipine and hydrochlorothiazide","companyName":"Hotel Dieu de France Hospital","companyId":"hotel-dieu-de-france-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This triple-combination antihypertensive reduces blood pressure by blocking angiotensin II receptors, relaxing vascular smooth muscle, and reducing sodium and fluid retention. Used for Hypertension (high blood pressure).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}